Home / Precision Medicine

Precision Medicine

RDx BioScience Genetic Risk Testing Identifies Harmful Mutation in BRCA1 or BRCA2 Human Genes Indicating Higher Likelihood of Breast Cancer

KENILWORTH, N.J.–(BUSINESS WIRE)–RDx BioScience (RDx) calls for increased use of genetic testing to identify mutations in BRCA1 and BRCA2, the genes discovered in the 1990s to be strongly associated with a high risk of breast cancer. RDX, a single source for care quality, risk evaluation and opioid expertise powered by a fast, full-service laboratory, raises awareness …

Read More »

Alexion Collaborates with Caelum Biosciences to Develop Targeted Therapy for Light Chain Amyloidosis

BOSTON & NEW YORK–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Caelum Biosciences today announced a collaboration to develop CAEL-101 for light chain (AL) amyloidosis. CAEL-101 is a first-in-class amyloid fibril targeted therapy designed to improve organ function by reducing or eliminating amyloid deposits in patients with AL amyloidosis. AL amyloidosis is …

Read More »

ASCO and Tempus Collaborate to Help Research Sites Identify Potential Participants for the Targeted Agent and Profiling Utilization (TAPUR) Study

ALEXANDRIA, Va. and CHICAGO, Jan. 10, 2019 (GLOBE NEWSWIRE) — The American Society of Clinical Oncology, Inc. (ASCO) and Tempus announced today an agreement to support research sites participating in ASCO’s Targeted Agent and Profiling Utilization (TAPUR™) Study. The TAPUR Study is a prospective, non-randomized clinical trial that aims to …

Read More »

Personal Genome Diagnostics and PathGroup Partner to Accelerate the Availability of Comprehensive Genomic Profiling with TMB

BALTIMORE–(BUSINESS WIRE)–Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, and PathGroup, a premier provider of anatomic, clinical and molecular laboratory services, announced today that they have entered into a co-development agreement for the PGDx elio™ tissue complete assay. This collaboration brings together PGDx’s scientific, development and regulatory expertise …

Read More »

Adaptive Biotechnologies and Genentech Enter Worldwide Collaboration and License Agreement to Develop Personalized Cellular Therapies for Treatment of Cancer

SEATTLE–(BUSINESS WIRE)–Adaptive Biotechnologies, an immune-driven medicine company, today announced that it will enter into a worldwide collaboration and license agreement with Genentech, a member of the Roche Group, to develop, manufacture and commercialize novel neoantigen directed T-cell therapies for the treatment of a broad range of cancers. The collaboration will …

Read More »

Onxeo Announces Identification of Predictive Biomarkers for AsiDNA, its First-in-Class DNA Damage Response Inhibitor

PARIS–(BUSINESS WIRE)–Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announces the identification of predictive biomarkers for AsiDNA™, its first-in-class non-targeted DNA Damage Response (DDR) inhibitor, which enables …

Read More »

Personal Genome Diagnostics Collaborates with Merck on Clinical Trial Evaluating Response to Dual Biomarker Directed Precision Oncology Combination Therapy

BALTIMORE–(BUSINESS WIRE)–Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today reported that its 500+ gene pan-cancer tumor profiling tissue assay is being used in Merck’s Phase 2 precision oncology KeyImPaCT study of biomarker-directed, pembrolizumab-based combination therapy for advanced non-small-cell lung cancer (NSCLC) (KEYNOTE-495). This study will investigate the …

Read More »

Horizon Pharma and HemoShear Therapeutics Enter Exclusive Drug Discovery Collaboration in Gout

DUBLIN & CHARLOTTESVILLE, Va.–(BUSINESS WIRE)–Horizon Pharma plc (Nasdaq: HZNP) and HemoShear Therapeutics, LLC, a privately held biotechnology company, today announced a collaboration to discover and develop novel therapeutics for gout. “As we continue to grow our pipeline, we are committed to addressing unmet treatment needs for people with gout as …

Read More »

Better Mouse Model Built to Enable Precision-Medicine Research for Alzheimer’s

Incorporating genetic diversity into a mouse model of Alzheimer’s disease resulted in greater overlap with the genetic, molecular and clinical features of this pervasive human disease, according to a study funded by the National Institute on Aging (NIA), part of the National Institutes of Health. The study also suggests that …

Read More »

Biocept and Prognos Partner to Apply Artificial Intelligence to Help Companies Optimize Commercialization of Biomarker-Targeted Therapies in Oncology

SAN DIEGO, Dec. 18, 2018 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, has entered into a Software License and Laboratory Data Supply Agreement with Prognos, Inc., an innovator in predicting disease …

Read More »